Novo Nordisk A/S Stock News

Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility.

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the wa

Wall Street is likely to record the fifth consecutive winning month despite volatility.

Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.

Novo Nordisk AS (NVO), maker of the weight-loss drug Wegovy, is set to acquire Cardior Pharmaceuticals, a German drug company, in a deal for up to 1.025 billion euros ($1.11 billion).

Novo Nordisk is one of the leading drugmakers in the world, developing hit medications such as Ozempic. The company is using artificial intelligence (AI) to process larger volumes of data from clinica

Terry Smith's Fundsmith Equity, the UK's most popular fund, has been downgraded by Morningstar due to questions over the manager's recent portfolio moves.  Fresh from the fund having underperformed

Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting cardiovascular disease.

Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabet

Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline.

Two of the year's biggest investment themes, artificial intelligence and anti-obesity drugs, are finally meeting up, as Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA announced a partnership

Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.

Novo Nordisk dominates the obesity and diabetes markets thanks to its long list of hit medications. Wegovy was just approved for an expanded indication, and Novo Nordisk's Amycretin could be its next

Eli Lilly and Novo Nordisk are fierce competitors in the diabetes and obesity markets. Each company is investing heavily to scale up production to meet demand.